Parkinson Disease 4, Autosomal Dominant Lewy Body Clinical Trials

Completed

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

NCT05594043

Conditions: Advanced or Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: Sanford Cancer Center ( Site 0300) Sioux Falls, South Dakota, United States

Princess Margaret Cancer Centre ( Site 0101) Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100) Montreal, Quebec, Canada

Hôpitaux Universitaires de Genève (HUG) ( Site 0202) Geneva, Canton of Geneva, Switzerland

View Trial Details

Completed

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations: University of South Alabama, Mitchell Cancer Institute ( Site 0065) Mobile, Alabama, United States

Providence Medical Foundation-Oncology ( Site 0069) Fullerton, California, United States

UCLA Hematology/Oncology - Santa Monica ( Site 0081) Los Angeles, California, United States

University of Colorado Cancer Center ( Site 0022) Aurora, Colorado, United States

View all 259 locations

View Trial Details

Completed

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

NCT03976323

Conditions: Carcinoma, Carcinoma, Nonsquamous Non-small-cell Lung, Neoplasms, +3 more
Locations: Alabama Oncology Bruno Cancer Center ( Site 0001) Birmingham, Alabama, United States

Northwest Alabama Cancer Center, PC ( Site 0002) Muscle Shoals, Alabama, United States

Disney Family Cancer Center ( Site 0005) Burbank, California, United States

Boca Raton Regional Hospital ( Site 0018) Boca Raton, Florida, United States

View all 178 locations

View Trial Details

Completed

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +9 more
Locations: Banner MD Anderson Cancer Center ( Site 0102) Gilbert, Arizona, United States

University of Colorado Anschutz Medical Campus ( Site 0104) Aurora, Colorado, United States

Georgia Cancer Specialists ( Site 0106) Atlanta, Georgia, United States

Parkview Research Center at Parkview Regional Medical Center ( Site 0130) Fort Wayne, Indiana, United States

View all 49 locations

View Trial Details

Completed

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

NCT04740307

Conditions: Advanced Hepatocellular Carcinoma, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: City of Hope Comprehensive Cancer Center ( Site 0002) Duarte, California, United States

Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013) Baltimore, Maryland, United States

Icahn School of Medicine at Mount Sinai ( Site 0009) New York, United States

Oregon Health and Science University ( Site 0006) Portland, Oregon, United States

View all 40 locations

View Trial Details

Completed

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

NCT04738487

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Boca Raton Regional Hospital ( Site 0004) Boca Raton, Florida, United States

Illinois Cancer Care ( Site 0026) Peoria, Illinois, United States

Mercy Research - Cancer and Hematology Center ( Site 0032) Springfield, Missouri, United States

Mercy Research - David C. Pratt Cancer Center ( Site 0025) St Louis, Missouri, United States

View all 188 locations

View Trial Details

Completed

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Banner MD Anderson Cancer Center ( Site 0001) Gilbert, Arizona, United States

City of Hope ( Site 0014) Duarte, California, United States

UCSF Medical Center at Mission Bay ( Site 0007) San Francisco, California, United States

Georgetown University ( Site 0036) Washington D.C., District of Columbia, United States

View all 39 locations

View Trial Details

Completed

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

NCT03516981

Conditions: Advanced Non-Small Cell Lung Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: Arizona Oncology Associates, PC- HAL ( Site 8001) Tempe, Arizona, United States

University of California Davis Comprehensive Cancer Center ( Site 0137) Sacramento, California, United States

University of California San Francisco ( Site 0111) San Francisco, California, United States

UCLA Hematology/Oncology -Santa Monica ( Site 0108) Santa Monica, California, United States

View all 81 locations

View Trial Details

Completed

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

NCT05017012

Conditions: Advanced or Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: James Lind Centro de Investigación del Cáncer ( Site 0102) Temuco, Araucania, Chile

FALP-UIDO ( Site 0101) Santiago, Region M. de Santiago, Chile

Bradfordhill ( Site 0100) Santiago, Region M. de Santiago, Chile

Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0021) Budapest, Pest County, Hungary

View all 22 locations

View Trial Details

Completed

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

NCT04305054

Conditions: Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, +11 more
Locations: The Angeles Clinic and Research Institute ( Site 2009) Los Angeles, California, United States

UCLA Hematology & Oncology ( Site 2004) Los Angeles, California, United States

Providence Saint John's Health Center ( Site 2010) Santa Monica, California, United States

University of Colorado, Anschutz Cancer Pavilion ( Site 2012) Aurora, Colorado, United States

View all 60 locations

View Trial Details

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Related conditions